Biotech ImmVirX bucks VC "desert" to bank $15m, with $25m in sight
The company’s virus targets and kills colorectal, gastric or ovarian cancer cells before multiplying and releasing particles to destroy the remaining tumour.
Source: afr.com
Fast, Ad-Free News Updates
Stay updated with breaking news from Venture Third Fund. Real-time updates on events, politics, business and more.